Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer
针对细胞周期改变改善晚期前列腺癌的治疗
基本信息
- 批准号:9343456
- 负责人:
- 金额:$ 36.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:Androgen ReceptorAndrogen SuppressionBindingBiological MarkersBiopsyBypassCDK4 geneCastrationCell CycleCell Cycle RegulationCellsChromatinClinicalClinical DataClinical ManagementClinical TrialsCollaborationsComplementComplexCyclin D1Cyclin-Dependent KinasesCytostaticsDataDependenceDevelopmentDiseaseDisease ProgressionDisease ResistanceDisease modelDisease stratificationFailureFundingGene ExpressionGoalsGrowthHypersensitivityInterventionInvestigationLaboratoriesLinkMalignant neoplasm of prostateMetastatic Prostate CancerModelingMolecularMolecular ProfilingPathway interactionsPatient-Focused OutcomesPatientsPhase I/II TrialPhenotypePhosphorylationPlayPredispositionProductionRecurrenceRegimenResistanceRoleSpecificityStratificationTestingTherapeuticTherapeutic InterventionTreatment EfficacyTreatment ProtocolsTreatment outcomeUp-Regulationactionable mutationadvanced diseasebasecancer therapycastration resistant prostate cancercytotoxiceffective therapyexperimental studygain of functionhormone therapyhuman diseaseimprovedinhibitor/antagonistneoplastic cellnoveloutcome predictionpersonalized medicinepre-clinicalprecision medicinepreventprostate cancer cellreceptorreceptor expressionresistance mechanismresponseresponse biomarkertargeted cancer therapytargeted treatmenttherapeutic developmenttherapy outcometreatment responsetreatment stratificationtumortumor progression
项目摘要
Abstract
Recent advances in understanding progression to castration-resistant prostate cancer (CRPC) has led to
development of therapeutics that slightly increase overall survival; however, the majority of patients with
CRPC succumb to disease within 2-3 years, indicating the need for metrics of precision medicine, and
development of additional therapeutics. Here, we propose an ambitious approach to stratify and enhance
treatment for metastatic CRPC to improve therapeutic outcomes, based on cell cycle alterations that we
recently discovered. The studies described will explore untouched territory with regard to PCa targeted
therapy based management, and will provide the first assessment of treatment based on subtyping in this
disease context. Moreover, the studies described could provide the first biomarker with which to stratify
prostate cancer treatment, and to improve therapy for patients with advanced disease. Our collective
findings strongly suggest that alterations in the RB-cyclin D1/CDK4 axis play major roles in disease
progression, and molecular investigation of these alterations provide a rational basis for disease
stratification and improved management of advanced PCa. This postulate will be challenged in
carefully planned specific aim. First, building on 2 funded clinical trials, we will use biopsy material, novel
models of disease, and co-clinical trials to challenge the hypothesis that the RB-cyclin D1/CDK4 axis can be
developed as biomarkers of response and as metrics for treatment stratification (Aim 1). These studies
have the potential for near-term patient benefit, and could identify the first biomarker for personalized
medicine in advanced PCa. Second, robust models will be used to interrogate the molecular basis of
responsiveness to therapeutic directed toward alterations in RB and/or cyclin D1 status (Aim 2). Studies
planned will provide critical information as to specificity and clinical placement of RB and cyclin D1-
alteration dependent interventions. Finally, targeting the Rb-cyclin D1/CDK4 axis forces reliance of tumor
cells on G2/M cyclin dependent kinases—plans were thereby developed to leverage this cell cycle
dependence, with a goal toward discovery of new means to maximize efficacy of treatment for cells with
RB-cyclin D1/CDK4 alterations (Aim 3). These collective aims build off the unique collaboration amongst a
leader in clinical management of advanced PCa and a pioneer of novel clinical trials (Dr. Kelly), and a
leading AR biologist with significant expertise in studying cell cycle regulation and PCa-associated cell cycle
alterations (Dr. Knudsen), and an expert in clinical targeting of cell cycle alterations (Dr. O’Dwyer). As
proposed, this project has the capacity to illuminate the means by which perturbations Rb-cyclin D1
alterations alter disease progression and therapeutic response in human disease, and to
dramatically alter PCa management.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAREN E KNUDSEN其他文献
KAREN E KNUDSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAREN E KNUDSEN', 18)}}的其他基金
相似海外基金
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
雄激素抑制与选择性淋巴结和剂量递增相结合。
- 批准号:
463259 - 财政年份:2022
- 资助金额:
$ 36.74万 - 项目类别:
Operating Grants
A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
氟班色林在接受雄激素抑制治疗前列腺癌的男性中的随机 II 期试验
- 批准号:
10195766 - 财政年份:2021
- 资助金额:
$ 36.74万 - 项目类别:
A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
氟班色林在接受雄激素抑制治疗前列腺癌的男性中的随机 II 期试验
- 批准号:
10407479 - 财政年份:2021
- 资助金额:
$ 36.74万 - 项目类别:
SWOG 9343--ANDROGEN SUPPRESSION & FIXED SCHEDULE SURAMINE IN PROSTATE CANCER
SWOG 9343--雄激素抑制
- 批准号:
6253166 - 财政年份:1997
- 资助金额:
$ 36.74万 - 项目类别:
SWOG 9343--ANDROGEN SUPPRESSION & FIXED SCHEDULE SURAMINE IN PROSTATE CA
SWOG 9343--雄激素抑制
- 批准号:
5224996 - 财政年份:
- 资助金额:
$ 36.74万 - 项目类别:














{{item.name}}会员




